TP53 and breast carcinoma: In previous studies (Bertheau et al, 2002, 2007), we have shown in non-inflammatory locally advanced breast cancers that TP53 mutations are highly predictive of complete pathological response to high-dose epirubicin/cyclophosphamide chemotherapy.